Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | PMM2 | O15305 | 2/20 | 0.36 |
| ▸ | MPI | P34949 | 2/20 | 0.36 |
| ▸ | PHOSPHO1 | Q8TCT1 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22819943 | 1.00 | NISCH (0.41) | NISCHACHETDP1L3MBTL1PIM1 | |
| SCHEMBL25488177 | 0.92 | ACHE (0.48) | NISCHACHETDP1MEN1KMT2A | |
| SCHEMBL10304925 | 0.84 | MEN1 (0.42) | NISCHACHETDP1MEN1KMT2A | |
| SCHEMBL29901001 | 0.82 | NISCH (0.52) | NISCHACHETDP1L3MBTL1PIM1 | |
| SCHEMBL30377758 | 0.82 | NISCH (0.52) | NISCHACHEABL1SLC9A1CA9 | |
| SCHEMBL13830012 | 0.82 | NISCH (0.52) | NISCHACHETDP1L3MBTL1PIM1 | |
| SCHEMBL9139591 | 0.82 | NISCH (0.52) | NISCHACHEABL1SLC9A1CA9 | |
| SCHEMBL13652436 | 0.82 | ACHE (0.42) | NISCHACHETDP1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29900999 | 0.80 | NISCH (0.50) | NISCHACHETDP1L3MBTL1PIM1 | |
| SCHEMBL24005592 | 0.78 | TSHR (0.42) | NISCHTDP1L3MBTL1PIM1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247969-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200290966-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-17 | — | — | US | disclosed |
| US-10570092-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-10343995-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190047957-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-14 | — | — | US | disclosed |
| US-10106503-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180179161-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-06-28 | — | — | US | disclosed |
| US-9926272-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170204061-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-07-20 | — | — | US | disclosed |
| US-9452161-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-09-27 | — | — | US | disclosed |
| US-20050113417-A1 | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-05-26 | — | — | US | disclosed |
| WO-2004106333-A1 | AZABICYCLOALKANE COMPOUNDS AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242622-A1 | Azabicycloalkane compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-02 | — | — | US | disclosed |
| WO-2004089892-A2 | DIARYLMETHYL AND RELATED COMPOUNDS HAVING BETA2 ANDRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040209860-A1 | compounds having a (biphenyl-2-yl)oxycarbonylamino- or (biphenyl-2-yl)aminocarbonylamino-substituted (2-7C)azacycloalkyl or (5-10C)azabicycloalkyl group; and a 2-(4-hydroxyphenyl)-2-hydroxyethylamino group; treating asthma or chronic obstructive pulmonary disease; providing bronchodilation | THERAVANCE RESPIRATORY COMPANY, LLC | 2004-10-21 | — | — | US | disclosed |
| US-20040209915-A1 | substituted with an N- (p-hydroxy-alpha-hydroxybenzylaminoalkylpiperidinyloxy- (or -amino-)carbonylamino group; useful for identifying compounds having both beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2004-10-21 | — | — | US | disclosed |
| WO-2004074812-A2 | LIBRARY OF BIPHENYL DERIVATIVES USEFUL FOR IDENTIFYING COMPOUNDS HAVING BOTH BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074276-A1 | BIPHENYL DERIVATIVES HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074246-A2 | BIPHENYL DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247969-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | NISCH 2978/4885ACHE 604/4885TDP1 3092/4885 |
| US-20170204061-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | NISCH 2978/4885ACHE 604/4885TDP1 3092/4885 |
| US-20190047957-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | NISCH 2978/4885ACHE 604/4885TDP1 3092/4885 |
| US-10343995-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | NISCH 2978/4885ACHE 604/4885TDP1 3092/4885 |
| US-10570092-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | NISCH 2978/4885ACHE 604/4885TDP1 3092/4885 |
| US-20040242622-A1 | Azabicycloalkane compounds | ADRB1, ADRB2, ADRA1B | NISCH 1605/4885ACHE 1014/4885TDP1 3978/4885 |
| US-10106503-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | NISCH 2978/4885ACHE 604/4885TDP1 3092/4885 |
| US-20040209915-A1 | substituted with an N- (p-hydroxy-alpha-hydroxybenzylaminoalkylpiperidinyloxy- (or -amino-)carbonylamino group; useful for identifying compounds having both beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRB1, ADRB2, ADRA2B | NISCH 2756/4885ACHE 534/4885TDP1 4437/4885 |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | ADRB1, ADRB2, ADRA2B | NISCH 2244/4885ACHE 1413/4885TDP1 4436/4885 |
| US-20200290966-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | NISCH 2978/4885ACHE 604/4885TDP1 3092/4885 |
| US-20050113417-A1 | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRA2B, ADRB2, ADRB1 | NISCH 2607/4885ACHE 348/4885TDP1 4373/4885 |
| US-20180179161-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | NISCH 2978/4885ACHE 604/4885TDP1 3092/4885 |
| US-20040209860-A1 | compounds having a (biphenyl-2-yl)oxycarbonylamino- or (biphenyl-2-yl)aminocarbonylamino-substituted (2-7C)azacycloalkyl or (5-10C)azabicycloalkyl group; and a 2-(4-hydroxyphenyl)-2-hydroxyethylamino group; treating asthma or chronic obstructive pulmonary disease; providing bronchodilation | ADRA2C, ADRB2, AHR | NISCH 3307/4885ACHE 811/4885TDP1 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.